Cadila Healthcare Ltd., also known as Zydus Cadila, on Thursday announced "successful" completion of phase two clinical trial of its biological therapy Pegylated Interferon alpha-2b, ‘PegiHepTM’ on Covid-19 patients.
In what now paves the way for phase three trials in India, Cadila said that the open-label, randomized, comparator controlled study was